Savara Inc (SVRA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US8051111016
Savara Inc financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -123.55 m USD |
| EBIT | -118.84 m USD |
| Net income | -118.84 m USD |
| Diluted EPS – continuing operations | -0.53 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
More stocks
- Ningbo Kbe Electrical Technology Co (300863.SZ)
- REPUBLIC AIRWAYS HOLDINGS INC. (RJET)
- Afya Ltd (AFYA)
- Jiangsu Shentong Valve Co Ltd (002438.SZ)
- Joeone Co Ltd (601566.SS)
- Green Plains Inc. (GPRE)
- Orchid Island Capital, Inc. (ORC)
- Gansu Yasheng Industrial Group Co Ltd (600108.SS)
- Zhejiang JW Precision Machinery Co.Ltd (300984.SZ)
- Jade Biosciences, Inc. (JBIO)
- Shanghai Hajime Advanced Material Technology Co. Ltd. (301000.SZ)
- Aussie Broadband Ltd (ABB.AX)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.